Category C Drug List Discussion Series

One of the most closely followed developments in China is the introduction of the Category C Drug List—the country’s first commercially funded national drug catalog. This marks a significant shift in China’s healthcare landscape, creating new pathways for innovative medicines.

NRDL+ is launching a dedicated discussion series to explore the implications of this development and provide strategic insights for global pharma.

If your team is interested in staying ahead of this critical development, join the waitlist here.

---